[
The pharma major’s revenue from operations in the March-ended quarter stood at Rs 8,506 crore, which was up 20% versus Rs 7,083 crore in the corresponding quarter of the last financial year.
The company recommended a final dividend of Rs 8 per equity share for the financial year 2024-25.
The profit after tax (PAT) was up 13% on the quarter-on-quarter basis versus Rs 1,413 crore in Q3FY25. All profits are attributable to equity holders of the company.
The topline surged 1.8% sequentially over Rs 8,359 crore reported in the October-December quarter of FY25.
In its global generics business, North America contributed revenue of Rs 3,559 crore, witnessing a 9% growth. The European business revenue jumped 145% to Rs 1,275 crore. This included revenues from the acquired NRT business of Rs 597 crore for Q4FY25. The India business revenue grew 16% YoY to Rs 1,305 crore from Rs 1,126 crore in Q4FY24.Company’s Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) stood at Rs 2,475 crore in the quarter under review which was 29% of the revenues.The pharmaceutical services & Active Ingredients (PSAI) also recorded a 16% YoY growth at Rs 956 crore versus Rs 822 crore in the year ago period.
Management take
Commenting on the results, Co-Chairman & MD, G V Prasad said that the company achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the US and the integration of the acquired NRT business. “We will continue to strengthen and grow our core businesses through portfolio management and operational,” he said.
https://img.etimg.com/thumb/msid-121030249,width-1200,height-630,imgsize-13576,overlay-etmarkets/articleshow.jpg
https://economictimes.indiatimes.com/markets/stocks/earnings/dr-reddys-labs-q4-results-cons-pat-jumps-22-to-rs-1594-crore-rs-8-per-share-dividend-announced/articleshow/121030267.cms
